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Background: Enhanced bleeding remains a serious problem after cardiac surgery, and fibrinolysis is often involved.
We speculate that lower plasma concentrations of plasminogen activator inhibitor – 1 (PAI-1) preoperatively and
tissue plasminogen activator/PAI-1 (t-PA/PAI-1) complex postoperatively might predispose for enhanced fibrinolysis
and increased postoperative bleeding.
Methods: Totally 88 adult patients (mean age 66 ± 10 years) scheduled for cardiac surgery, were enrolled into
a prospective study. Blood samples were collected pre-operatively, on admission to the recovery and at 6 and
24 hours postoperatively. Patients with a surgical bleeding that was diagnosed during reoperation were discarded
from the study. The patients were allocated to two groups depending on the 24-hour postoperative chest tube
drainage (CTD): Group I > 500ml, Group II ≤ 500ml. Associations between CTD, PAI-1, t-PA/PAI-1 complex and
D-dimer were analyzed with SPSS.
Results: Nine patients were excluded because of surgical bleeding. Of the 79 remaining patients, 38 were
allocated to Group I and 41 to Group II. The CTD volumes correlated with the preoperative plasma levels of PAI-1
(r = − 0.3, P = 0.009). Plasma concentrations of preoperative PAI-1 and postoperative t-PA/PAI-1 complex differed
significantly between the groups (P < 0.001 and P = 0.012, respectively). Group I displayed significantly lower
plasma concentrations of fibrinogen and higher levels of D-dimer from immediately after the operation and
throughout the first 24 hours postoperatively.
Conclusions: Lower plasma concentrations of PAI-1 preoperatively and t-PA/PAI-1 complex postoperatively leads
to higher plasma levels of D-dimer in association with more postoperative bleeding after cardiac surgery.
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Increased per – and postoperative bleeding remains to
be a serious problem in cardiac surgery. Alterations in
hemostasis per - and postoperatively may have a diver-
sity of etiologies. These include the surgery per se
as well as effects of the cardiopulmonary bypass (CPB)
on the coagulation and the inflammation cascades,
and their cross-reactions with the fibrinolytic – and
the kinin-kallikrein systems [1-3]. During the last few
years, increasing attention has been paid to reports* Correspondence: agnese_krauze@yahoo.com
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reproduction in any medium, provided the ordemonstrating the influence of the fibrinolytic system
on increased bleeding, particularly after cardiac surgery
employing CPB [1,4-6].
Plasminogen, alpha-2 antiplasmin, tissue plasminogen
activator (t-PA) and urinary type plasminogen activator
are the main fibrinolytic components of plasma. The
generation of plasmin is mainly regulated by processes
involving t-PA and its counterpart plasminogen activator
inhibitor type – 1 (PAI-1), which blocks the conversion
of plasminogen to plasmin, thus inhibiting fibrinolysis
[7,8]. PAI-1 is a serine protease, which is synthesized in
platelets as well as in endothelium and adipose tissues
[9]. PAI-1 binds rapidly with a ratio of 1:1 to t-PA form-
ing a stable t-PA/PAI-1 complex, which is cleared froml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formation of the t-PA/PAI-1 complex depends on the
plasma concentrations of the two proteins: the higher
the concentrations of t-PA and PAI-1, the more complex
will be formed in the circulation [10].
Cardiac surgery employing CPB is associated with
increased fibrinolytic activity and enhanced concentra-
tions of PAI-1 and D-dimer as compared to off-pump
surgery [11-13]. However, inter-individual variations in
PAI-1 and t-PA/PAI-1 complex formation are relatively
large. After normal primary hemostasis, low PAI-1 and
low t-PA/PAI-1 complex plasma concentrations, may
result in hyperfibrinolytic hemorrhage [8]. This implies
that clots are primarily formed, but fibrinolysis occurs
readily since the half-life of PAI-1 is short and the
process might lead to relative lack of inhibitor to abate
the plasmin activity.
We hypothesize that control of the fibrinolytic system
pre – and postoperatively strengthen the possibilities
of predicting enhanced bleeding after cardiac surgery.
Therefore, our aim was to assess fibrinolytic activity
pre- and postoperatively in patients undergoing cardiac
surgery with the use of CPB.
Methods
The study protocol and the informed consent form
were approved by the Ethics Committee (No.151209-4L)
of Pauls Stradins Clinical University Hospital, Riga,
Latvia. Written informed consent was obtained from
every patient.
Population
Between 1 May and 30 December 2010, 88 consecutive
adult patients, who were admitted to the hospital to
undergo cardiac surgery by the use of CPB, were consid-
ered for a prospective observational study. None of the
patients received antifibrinolytic medicines during - or
after the surgery.
Inclusion and exclusion criteria
Inclusion criteria: > 18 years of age, first-time coronary
artery bypass grafting (CABG) and/or valve replacement
under CPB, EuroSCORE [14] < 10%, coagulation tests
within normal ranges at baseline {prothrombin time
(PT) 70-120%} or international normalized ratio (INR)
0.8-1.2, fibrinogen plasma concentration 1.5 – 3.5 g/L,
platelet count (PLT) 150 – 400 × 109/L, hemoglobin
(Hb) concentration > 135 g/L for men and > 120 g/L for
women) and no anticoagulant, - anti-aggregating or
non-steroidal anti-inflammatory drugs for, at least, five
days prior to surgery in order to disclose drug-induced
platelet dysfunction. The last dose of low-molecular-
weight heparin (LMWH) was administered the evening
before the surgery. Exclusion criteria: emergency - andredo operations, preoperative hemostatic disorders with
a history of hemorrhagic events or coagulopathy (PT
below 50% or INR greater than 1.5, fibrinogen plasma
concentration below 1.5 g/L, PLT lower than 100 × 109/L)
and severe renal and/or hepatic dysfunctions.
Perioperative management
Anesthesia was induced with fentanyl (Fentanyl-
KalceksW 0.05 mg/ml, A/S Kalceks, Latvia), 0.2-0.3 mg,
midazolam (DormicumW, F. Hoffman-La Roche AG,
Switzerland), 2.5-5 mg, propofol (Propofol-LipuroW
10mg/ml, B. Braun Melsungen AG, Germany) 1–3 mg/kg
and cisatracurium (NimbexW 2 mg/ml, GlaxoSmithKline
Manufacturig S.p.A, Italy) 0.2 mg/kg intravenously and
maintained with inhalation of sevoflurane (Sevoflurane
PiramalW, Piramal Healthcare Ltd, United Kingdom) at
0.8-1.2 MAC. Before the start of CPB, heparin (Pan-
Heparin SodiumW, Panpharma S.A./Rotexmedica Gmbh,
Germany) was administered at a dose of 300–400 units/
kg followed by 5.000 - 10.000 units to maintain an acti-
vated coagulation time (ACT) above 480 seconds. Dur-
ing CPB (AdmiralW, Eurosets TM, Italy), anesthesia was
maintained with fentanyl 0.03-0.06 mkg/kg/min, propo-
fol 3–5 mg/kg/h and cisatracurium 0.1 mg/kg/h. Patients
were cooled to a bladder temperature of 34–35°C. Myo-
cardial protection was achieved by using St. Thomas 4:1
cardioplegia (AlleManW, Germany). Weaning off CPB
after the surgery was performed after the patient was
rewarmed to a bladder temperature above 36°C. After
separation from CPB, protamine (Protamin MedaW,
Meda Pharma, Austria) was administered at a dose of
1 mg per 100 units of heparin followed by additional
doses until ACT had returned to baseline. Postopera-
tively, standard unfractionated heparin was administered
from 20–24 hours after valve surgery. Warfarin
(OrfarinW, Orion Pharma, Finland) treatment was
resumed on the third postoperative day if the patient
had no signs of bleeding or need for re-operation.
LMWH (FragminW 2500 IU/1ml, Pfizer, Belgium) was
also started 20–24 hours after CABG in patients without
increased bleeding tendency. According to our clinical
guidelines, a hematocrit < 26% indicated requirement
for transfusion of packed erythrocytes; PT < 50%, and
PLT < 90 × 109/l indicated need for transfusion of freshly
frozen plasma and platelet concentrates, respectively. In
conditions of increased bleeding with drop in fibrinogen,
cryoprecipitate was given.
Demographic and laboratory data
We noticed the following demographic and perioperative
variables: age, sex, body mass index (BMI), ejection
fraction (EF), comorbidities, preoperative anticoagula-
tion therapy, type of surgery, extracorporeal circulation
time (min), aortic clamp - and reperfusion times, and
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preoperatively and t-PA/PAI-1 complex 24 hours post-
operatively. PAI-1 (normal range 1–25 ng/ml) and t-PA/
PAI-1 complex (normally < 5 ng/ml) were determined
by using enzyme-linked immunosorbent assay (ZYMUT-
EST, HYPHEN BioMed, France). Cross-linked fibrin
degradation products (D-dimer, normally < 300 ng/ml)
were quantified with the immunoturbidimetric test (D-
dimer PLUS, Dade Behring, Marburg, Germany). Fibri-
nogen plasma concentration was determined according
to Clauss [15]. PT was analyzed with a prothrombin
complex assay (Lyophilized DadeW and InnovinW, Sie-
mens Healthcare Diagnostics, USA). All the coagulation
tests were determined using SysmexW CA-1500 (Siemens
Healthcare Diagnostics, Germany). Hb and PLT were
analyzed by means of a Beckman Coulter LH 750
Hematology Analyzer.
Groups of patients
Bleeding volume was recorded as milliliters of chest tube
drainage (CTD) 24 hours (h) postoperatively and the
patients were allocated to two groups; Group I: bleeding
arbitrarily defined as CTD > 500 ml/24h and Group II
with CTD ≤ 500 ml/24h. Indication for reoperation
because of suspected surgical bleeding was based on
evaluation of clinical and hemodynamic changes. If the
patient was re-operated, the CTD volume until reopera-
tion, and 24 hours afterwards was registered. A surgical
bleeding was diagnosed only if one or more specific
bleeding sites were identified. Then, the patient was
excluded from further study. If no specific site was
located, the bleeding was registered as hemostatic dis-
order and the patient was allocated to the most appro-
priate group according to the bleeding volume. Plasma
fibrinogen, PT, PLT and Hb were assessed preoperatively
(T0) and together with D-dimer upon admission to
the intensive care unit (T1), and at 6 and 24 hours (T6,
T24) postoperatively.
Statistical analysis
Data was analyzed with SPSS (SPSSW version 17.0,
Chicago, IL). Continuous variables were presented as
mean ± standard deviation (SD) and categorical variables
as percentages (%). Linear regression (Pearson’s correl-
ation coefficient) was used to analyze the relationships
between the demographic and the surgical data and the
hematologic -, coagulation – and fibrinolysis parameters
(PAI-1, t-PA/PAI-1 complex and D-dimer) and bleeding
volumes, respectively. Comparisons between the groups
were performed with Mann–Whitney U test for non-
parametric variables, and two-sample t test or ANOVA
for parametric variables. Chi-square test was used
to analyze categorical data. Statistical significance was
defined as a P< 0.05.Results
Clinical course
Totally 88 consecutive patients (47 men and 41 women)
66 ± 10 years (mean ± SD) of age scheduled for cardiac
surgery were considered for inclusion. Eleven patients
(12.5%) required reoperation between 10 minutes and
62 hours postoperatively, seven of them within 24 hours
because of suspected surgical bleeding or hemipericar-
dium, and they all survived. A surgical bleeding site was
identified in nine patients (10.2%) that were discarded
from further data analysis. In two patients, a specific site
was not found and they were allocated to Group I.
As surveyed in Table 1, 79 patients were subjected to
further analysis: 38 patients were diagnosed with a CTD
> 500 ml/24h (Group I), whereas 41 patients were regis-
tered with a postoperative CTD ≤ 500 ml/24h (Group
II). We found significant differences in 24 hour CTD
and transfusion requirements between the groups.
Moreover, we noticed no significant intergroup differ-
ences in demographic characteristics (mean age, gender,
BMI, EF, comorbidities, preoperative medication or sur-
gical variables) or in preoperative coagulation tests (PT,
APTT, fibrinogen and PLT).
Variables of fibrinolysis
As shown in Figure 1, both the mean plasma concentra-
tion of PAI-1 preoperatively (A) and of t-PA/PAI-1 com-
plex 24 hours postoperatively (B), were lower in Group I
(P < 0.001 and P = 0.01, respectively). Postoperatively,
mean plasma concentrations of fibrinogen increased less
from T1 and beyond in Group I as compared to Group
II (P = 0.01) as depicted in Figure 2A. Concomitantly,
the mean plasma concentrations of D-dimer were sig-
nificantly higher (P < 0.05) in Group I as compared to
Group II (Figure 2B).
Associations between postoperative bleeding and
variables of fibrinolysis
We found no correlation between demographic and sur-
gical parameters and the plasma concentrations of PAI-1
and t-PA/PAI-1 complex. However, preoperative PAI-1
levels correlated inversely with 24 hour postoperative
blood loss (Figure 3; r = − 0.3, P = 0.009). In con-
trast, the correlation between t-PA/PAI-1 complex and
24 hour blood loss did not reach statistical significance
(r = − 0.24, P = 0.08).
Discussion
The present study revealed that lower levels of PAI-1
preoperatively and of t-PA/PAI-1 complex postopera-
tively, are associated with lower plasma concentrations
of fibrinogen, higher levels of D-dimer and increased
blood loss during the first 24 hours after the opera-
tion. Our results are consistent with several recent
Table 1 Demographic characteristics and co-morbidities of patients with postoperative bleeding after cardiac surgery
employing cardiopulmonary bypass
Variables I Group n=38 II Group n=41 P value
Demographic
Sex (male/female) 21/17 17/24 0.5
Age (years) 67 ± 10 66 ± 10 0.7
EuroSCORE (%) 4.8 ± 2 4.9 ± 1.7 0.2
BMI (kg/m2) 27.6 ± 4.8 28.3 ± 4.6 0.5
EF (%) 55 ± 8.8 56 ± 6.7 0.2
Hypertension (n) 13 22 0.1
Previous myocardial infarction (n) 13 13 1.0
Hypercholesterolemia (n) 6 11 0.2
Pulmonary obstructive disease (n) 5 3 0.48
Preoperative medication
Aspirin (n) 26 29 0.7
Clopidogrel (n) 6 9 0.44
LMWH (n) 31 25 0.42
Warfarin (n) 2 1 0.6
Preoperative coagulation tests
PT (%) 87 ± 15 92 ± 12 0.15
APTT (sec.) 34 ± 6 32 ± 4 0.05
Fibrinogen (g/L) 4.4 ± 1.1 4.7 ± 1.5 0.25
PLT (x109/L) 205 ± 39 225 ± 72 0.24
Surgical parameters
CABG (n) 16 17 0.9
Valve replacement (n) 13 16 0.6
Combined surgery (n) 8 9 0.8
CPB duration (min) 106 ± 40 102 ± 41 0.8
Aorta occlusion time (min) 66 ± 25 64 ± 29 0.4
Reperfusion time (min) 35 ± 15 32 ± 15 0.5
Blood loss 24h (ml) 812 ± 269 346 ± 102 <0.001
Erythrocyte requirements during ICU stay (n) 14 3 0.008
Plasma requirements during ICU stay (n) 14 1 0.001
Cryoprecipitate requirements during ICU stay (n) 7 1 0.03
Data are presented as mean ± SD or number (n).
BMI, body mass index; EF, ejection fraction; LMWH, low molecular weight heparin; PT, prothrombin time; APTT, activated partial thromboplastin time; PLT, platelet
count; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; ICU, intensive care unite; n, number of patients.
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system is associated with increased postoperative bleed-
ing in cardiac surgery employing CPB [1,5,12].
The plasma concentrations of PAI-1 and t-PA/PAI-1
complex that are supposed to be the main regulators of
fibrinolysis in humans, are both characterized by wide
variations that may explain the large inter - individual
differences in fibrinolytic activity [16]. Several recent
studies have described the influence of genetic factors,
such as PAI-1 promoter – 675 (4G/5G) polymorphism,
on the plasma levels of PAI-1, t-PA and t-PA/PAI-1complex [1,4,6,17-20]. The 5G allele is associated with
low levels of PAI-1 [4,6,17,19].
Our patients were cooled on CPB to a bladder
temperature of 34–35°C with no intergroup difference.
Some investigators claim that reduced temperature
lowers endogenous production of PAI-1, resulting in
enhanced fibrinolysis and increased per- and pos-
toperative bleeding [21] whereas others refute this idea
[22]. Our patients were rewarmed to normal body
temperature before transfer to the recovery. Therefore,
it is unlikely that temperature had any influence on the
Figure 1 (A) Preoperative plasma concentration of
plasminogen activator inhibitor type-1. (B) Postoperative plasma
concentration of tissue plasminogen activator/plasminogen activator
inhibitor type-1 complex. Group I, patients with postoperative blood
loss of > 500 ml/24 hours; Group II, patients with postoperative
blood loss of ≤ 500 ml/24 hours PAI-1, plasminogen activator
inhibitor type − 1; t-PA-PAI-1: tissue, plasminogen activator/
plasminogen activator inhibitor type-1 complex. Data are presented
as mean ± SD.
Figure 2 (A) Plasma concentrations of fibrinogen: at baseline
(TO), upon admision to the intensive care unit (T1), six hours
after surgery (T6) and twenty-four hours after surgery (T24).
(B) Postoperative plasma concentrations of D-dimer: upon admission
to the intensive care unit (T1) six hours after surgery (T6) and
twenty-four hours after surgery (T24). Group I, patients with
postoperative blood loss of >500 ml/24 hours; Group II, patients
with postoperative blood loss of ≤ 500 ml/24 hours. Data presented
as mean ± SD.
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stable indicator of fibrinolysis, as compared to t-PA,
whose concentration peaks during CPB, we determined
PAI-1 before the operation and t-PA/PAI-1 complex
after the surgery [23] as well as their associations with
postoperative blood loss 24 hours after the surgery. Our
results indicated that those presenting with higher pre-
operative plasma concentrations of PAI-1 had less blood
loss, and conversely, those with a lower preoperative
plasma level had a larger blood loss 24 hours after sur-
gery. Other investigators have noticed similar results
[1,24]. Recently, investigators have reported favorable
effects of administration of very long half-life PAI-1
(> 700 hours) on bleeding time and total blood loss after
tail clip in PAI-1 deficient mice [25]. However, so far,
very long half-life PAI-1 is not available as a medicine to
promote hemostasis after surgery, trauma, or PAI-1 defi-
ciency in humans.As to the best of our knowledge, the literature is
scanty on reports focusing on the importance of t-PA/
PAI-1 complex and its relationship with enhanced bleed-
ing after CPB. Our notion that patients with an accumu-
lated blood loss in excess of 500 ml 24 hours after CPB
had lower levels of t-PA/PAI-1 complex is consistent
with the findings reported by Rivera and coworkers [1].
In a subgroup of patients presenting with enhanced
bleeding, these workers reported lower levels of PAI-1
both before - and after surgery and lower concentrations
of t-PA/PAI-1 complex postoperatively. Surprisingly, we
observed no significant correlation between the pre-
operative concentration of PAI-1 and the level of t-PA/
PAI-1 complex 24 hours postoperatively. We speculate
that the lack of such correlation can be explained by the
fact that the increase in PAI-1 production culminates on
Figure 3 Relationships between preoperative plasma
concentrations of plasminogen activator inhibitor type - 1
and blood loss over 24 hours of patients subjected to cardiac
surgery employing cardiopulmonary bypass. *P < 0.05. PAI-1:
plasminogen activator inhibitor type - 1.
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normal on the second postoperative day [23]. The
plasma levels of PAI-1 are known to increase immedi-
ately after CPB as part of the „fibrinolytic shut-down”
[26] and afterwards, it decreases slowly over the subse-
quent days or weeks [27].
Lower preoperative levels of PAI-1 and lower t-PA/
PAI-1 complex ratio 24 hours after surgery might have
led to higher levels of D-dimer immediately after the
surgery [28,29]. Kuepper and co-workers [5] examined
120 patients scheduled for cardiac surgery who were
randomized to an aprotinin group and a control group.
D-dimers reached higher plasma levels in the control
group indicating increased fibrinolysis. Consistently, in
our study, the patients of Group I (with the highest
blood loss) had significantly lower fibrinogen - and
higher D-dimer levels after surgery and throughout
the ensuing 24 hours (Figure 2). The significantly lower
fibrinogen level in Group I immediately after the surgery
might indicate increased consumption because of the
hyperfibrinolytic state of this group. These findings are
also supported by the contention of previous workers
that plasmin generation and fibrin degradation is increased
10-to 20-fold during CPB, and moreover that fibrin for-
mation and degradation rates are nearly equally affected
by the CPB [2,30].
Our study has limitations. That we found no associa-
tions between preoperative PAI-1 and postoperative
t-PA/PAI-1 complex could be due to a small sample size.
By considering the first 25 patients included in each
group, calculation of sample size revealed that the cor-
relation between t-PA/PAI-1 complex and blood loss
after 24 hours (r = − 0.24, P = 0.08) was underpoweredand might have reached statistical significance (P<0.05
and a power of 80%) first by increasing the total number
of patients to 134 (n = 67 in each group). Another weak-
ness is that we did not analyze patient outcome data.
An attractive idea for a future investigation would be
to determine t-PA and PAI-1 activity separately and in
concert with t-PA/PAI-1 complex concentrations. This
would increase our understanding of the relationship be-
tween free PAI-1 antigen and its formation of t-PA/PAI-1
complex. Moreover, a multicenter study should be
performed focusing on the influence of the fibrinolytic
system on postoperative bleeding and its relation to out-
come after cardiac surgery.
Conclusions
Taking into account the complexity of enhanced bleed-
ing after cardiac surgery, it might be difficult to isolate
one factor as the denominator of bleeding. Our investi-
gation indicates that low plasma levels of PAI-1 pre-
operatively and of t-PA/PAI- 1 complex postoperatively,
in parallel with increased plasma concentration of
D-dimer can be useful predictors of fibrinolysis, and
thus, of increased postoperative blood loss. Therefore,
by including screening of fibrinolytic markers pre – and
postoperatively, we might be able to identify patients with
low fibrinolytic inhibitory potential who might benefit
from antifibrinolytic therapy prior to cardiac surgery.
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